Human medicines European public assessment report (EPAR): Onbrez Breezhaler, indacaterol, Date of authorisation: 29/11/2009, Revision: 20, Status: Authorised

Workshop on the use of external controls for evidence generation in regulatory decision-making, Online, European Medicines Agency, Amsterdam, the Netherlands, from 3 November 2025, 10:00 (CET) to 3 November 2025, 17:30 (CET)

Human medicines European public assessment report (EPAR): Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan, efavirenz,emtricitabine,tenofovir disoproxil, Date of authorisation: 05/09/2017, Revision: 18, Status: Authorised

Human medicines European public assessment report (EPAR): Prevenar 20 (previously Apexxnar), pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed), Date of authorisation: 14/02/2022, Revision: 12, Status: Authorised

Medicine shortages: EMA public webinar putting patients first, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 4 November 2025, 14:00 (CET) to 4 November 2025, 16:00 (CET)

Human medicines European public assessment report (EPAR): Inhixa, enoxaparin sodium, Date of authorisation: 15/09/2016, Revision: 30, Status: Authorised

Podcast: Inside EMA

Human medicines European public assessment report (EPAR): Truvada, emtricitabine,tenofovir disoproxil, Date of authorisation: 20/02/2005, Revision: 49, Status: Authorised

Human medicines European public assessment report (EPAR): Vizamyl, flutemetamol (18F), Date of authorisation: 22/08/2014, Revision: 20, Status: Authorised

Scientific advice and protocol assistance adopted during the CHMP meeting 10-13 November 2025